Role of metronidazole in radiation therapy: a review of 717 cancer cases

The presence of hypoxic cells in a tumor decreases their radiosensitivity; which blocks the efficacy of external tele cobalt irradiation. So a study was undertaken in various cancer patients to observe the role of metronidazole as a selective radiosensitizer. 717 cancer cases were enlisted and were divided into a study and control group. The study group were given metronidazole at a dose of 2 grams orally, 4 hours before each irradiation, (5 days in a week) for 6-7 weeks. The control group were devoid of it. After completion of the treatment, as well as, after 3 years follow-up, it was observed that the patients receiving metronidazole had better treatment response and more number of recurrence free years. Since it is a cheaper drug it can be used freely in the form of a potential radiosensitizer, for external irradiation therapy. (author). 10 refs., 2 tabs